
Wells Fargo Active Cash vs. Wells Fargo Reflect: Do you want rewards or an intro APR?
The Wells Fargo Active Cash® Card and Wells Fargo Reflect® Card can both save you money — but in different ways. Which one is right for you depends on whether you prefer a longer intro-APR period or rewards. In other words, would you rather avoid interest (for a time) or earn cash back?
Below, CNBC Select dives into the details of what each credit card offer, so you make the best choice for you.
None
None
$0
0% intro APR for 21 months from account opening on purchases and qualifying balance transfers.
17.24%, 23.74%, or 28.99% variable APR
5%, min: $5
3%
Excellent/Good
See rates and fees, terms apply.
Unlimited 2% cash rewards on purchases
Earn a $200 cash rewards bonus after spending $500 in purchases in the first 3 months
$0
0% intro APR for 12 months from account opening on purchases and qualifying balance transfers.
19.24%, 24.24%, or 29.24% Variable APR
Intro balance transfer fee of 3% for 120 days from account opening, then up to 5%, min: $5
3%
Excellent/Good
See rates and fees, terms apply.
The Wells Fargo Active Cash® Card and Wells Fargo Reflect® Card both have no annual fee.
Winner: Tie
With the Wells Fargo Active Cash® Card, you can earn $200 in cash rewards after you spend $500 in purchases within the first three months. You'll also receive an intro APR period for purchases and qualifying balance transfers that last 12 months.
The Wells Fargo Reflect® Card has no welcome bonus, but you'll receive a longer intro APR offer, lasting 21 months. That makes the card more useful if you have lots of high-interest credit card debt. However, the Active Cash provides the opportunity to earn an upfront cash bonus and has a lower intro-balance transfer fee.
Winner: Wells Fargo Active Cash
The Wells Fargo Active Cash® Card is a flat-rate 2% cash-back credit card. The Active Cash earns 2% in cash rewards on every purchase, which you can redeem for gift cards, statement credits, direct deposits (into eligible Wells Fargo accounts) and more. The Wells Fargo Reflect® Card doesn't earn rewards.
Winner: Wells Fargo Active Cash
The Wells Fargo Reflect® and Wells Fargo Active Cash® both provide some basic protections, including:
The cell phone coverage can be valuable because you can be reimbursed up to $600 per claim for up to two claims every 12 months (a $25 deductible applies). However, the rental car insurance is secondary, so it only covers what your other insurance doesn't.
The Active Cash Card also has travel and emergency assistance services and provides access to the Visa Signature Concierge and Luxury Hotel Collection.
Winner: Wells Fargo Active Cash
Offers in this section are from affiliate partners and selected based on a combination of engagement, product relevance, compensation, and consistent availability.
Good to Excellent670–850Earn 100,000 bonus points
On Chase's site
See rates and fees. Terms apply.
Good to Excellent670–850Earn $250 cash back
On Chase's site
See rates and fees. Terms apply.
Overall, the Wells Fargo Active Cash® Card is a better credit card for most people. It has a straightforward and rewarding cash-back program. Plus, you'll get an intro-APR offer, which means you can save money in multiple ways with the Active Cash Card.
The Wells Fargo Reflect® does one thing and it does it exceptionally well—reduce your interest payments. If you're working your way out of credit card debt or need to finance a purchase, the Reflect card can be a better choice. Just be sure to consider this card's higher balance transfer fee when you're running the numbers.
Many rewards cards require you to have a good to excellent credit score to qualify. That makes higher-tier rewards cards an unlikely option for anyone with poor credit or no credit history.
If you have trouble paying your bills on time, a card with a 0% APR period might tempt you to spend more than you can handle.
Money matters — so make the most of it. Get expert tips, strategies, news and everything else you need to maximize your money, right to your inbox. Sign up here.
At CNBC Select, our mission is to provide our readers with high-quality service journalism and comprehensive consumer advice so they can make informed decisions with their money. Every personal finance article is based on rigorous reporting by our team of expert writers and editors with extensive knowledge of financial products. While CNBC Select earns a commission from affiliate partners on many offers and links, we create all our content without input from our commercial team or any outside third parties, and we pride ourselves on our journalistic standards and ethics.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Wall Street Journal
19 minutes ago
- Wall Street Journal
Treasury Yields Rise on Stable Employment Ahead of CPI
1600 ET – U.S. job creation slows less than expected, reducing odds of a dovish Fed. Bond markets react with a selloff that boosts yields. May's job creation slows less than forecast and unemployment remains at 4.2%. CME data show diminishing odds of a rate cut before September. Two or more cuts this year still represent the highest odds, but bets on only one or no cut rise. Wells Fargo foresees May's 12-month core CPI, due Wednesday, accelerating to 3.3% from April's 2.8%. The 10-year gains 0.089 percentage point this week, including 0.155 p.p. today, to 4.507%. The two-year rises 0.125 p.p. in the week and 0.115 p.p. today, to 4.039%. ( @ptrevisani) 0846 ET – U.S. job creation didn't slow as much as expected in May, spurring a bonds selloff that takes Treasury yields higher. May payrolls slowed to 139,000 from a downwardly revised 147,000. Economists surveyed by WSJ forecast 125,000. Unemployment was unchanged at 4.2%, as expected. The data likely supports expectations of a Fed hold. Yields were already rising ahead of payrolls, as markets watched the Trump-Musk break up. They rose faster after the data, particularly in longer maturities. The 10-year trades at 4.452%% and the two-year at 3.985%. ( @ptrevisani)
Yahoo
13 hours ago
- Yahoo
Petco price target raised to $2.50 from $2.10 at BofA
BofA raised the firm's price target on Petco (WOOF) to $2.50 from $2.10 and keeps an Underperform rating on the shares after the company reported fiscal Q1 adjusted EBITDA ahead of consensus. The firm raised its FY26 adjusted EBITDA view to $386M from $381M to reflect Q1 upside and raised its FY26 adjusted EPS view by 2c to 11c, noted the analyst. While Petco continues to make progress on cost transformation efforts before it 'shifts back to growth/offense,' the firm sees continued same-store sales softness in the near-term as well as longer-term risk that market share erosion could continue, the analyst tells investors. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on WOOF: Disclaimer & DisclosureReport an Issue Petco price target lowered to $4.50 from $5 at Morgan Stanley Petco Health and Wellness Faces Challenges Amid Declining Sales and Market Share Risks Petco price target raised to $3.50 from $3 at Wells Fargo Petco Reports Q1 2025 Results, Reaffirms Outlook Closing Bell Movers: Lululemon falls over 20% on soft guidance Sign in to access your portfolio


Business Upturn
14 hours ago
- Business Upturn
Lupin gets U.S. FDA tentative approval for Generic Oxcarbazepine ER Tablets
Lupin Limited has announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Oxcarbazepine Extended-Release (ER) Tablets in 150 mg, 300 mg, and 600 mg strengths. These tablets are the generic equivalent of Oxtellar XR® ER Tablets by Supernus Pharmaceuticals and are indicated for the treatment of partial-onset seizures in patients aged 6 years and above. Lupin's version of the drug will be manufactured at its Nagpur facility in India. According to IQVIA MAT April 2025 data, Oxcarbazepine ER Tablets (RLD Oxtellar XR®) recorded estimated annual sales of USD 206 million in the United States, underscoring the potential market opportunity for Lupin. Headquartered in Mumbai, Lupin is a leading global pharmaceutical company with a strong footprint in the U.S. and India. The company focuses on a broad range of therapy areas including central nervous system disorders, respiratory, cardiovascular, anti-infective, and women's health. It operates 15 manufacturing sites and 7 research centers globally, supported by over 23,000 employees. Lupin continues to expand its U.S. portfolio of complex generics and remains committed to delivering high-quality, affordable medicines that improve health outcomes for patients around the world. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at